Characterization of adenylyl cyclase in heart sarcolemma in the absence or presence of alamethicin.
Alamethicin is commonly used as an agent for unmasking the latent enzyme activities in vesicular membrane preparations; however, relatively little is known about the effect of this agent on the characteristics of adenylyl cyclase in heart sarcolemma. By employing rat heart sarcolemmal preparation, we observed 5 to 6 fold increase in adenylyl cyclase activity upon treatment with alamethicin. Kinetic experiments using various concentrations of MgATP revealed that the increase in adenylyl cyclase activity in alamethicin treated membranes was associated with an increase in Vmax as well as affinity of the substrate for the enzyme. Dose-responses of the control and alamethicin-treated preparations to various activators of adenylyl cyclase revealed that the sensitivity of the enzyme to forskolin, NaF and GppNHp, was markedly increased upon treating sarcolemma with alamethicin. The activation of adenylyl cyclase by forskolin was also enhanced by increasing the concentration of alamethicin in the incubation medium. Furthermore, there was a greater increase in adenylyl cyclase activity with different concentrations of Mn2+ in the presence of alamethicin. These results suggest that alamethicin treatment alters the characteristics of adenylyl cyclase in addition to unmasking the enzyme activity in the purified sarcolemmal vesicular preparation.
Division of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada.
R
R
Sethi
K S
KS
Dhalla
K R
KR
Shah
N S
NS
Dhalla
D000255:Adenosine Triphosphate / Q000494:pharmacology; D000262:Adenylyl Cyclases / Q000378:metabolism*; D000408:Alamethicin / Q000494:pharmacology*; D000818:Animals; D005576:Colforsin / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D019204:GTP-Binding Proteins; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology; D007700:Kinetics; D009206:Myocardium / Q000378:metabolism*; D051381:Rats; D011943:Receptors, Adrenergic, beta; D012508:Sarcolemma / Q000187:drug effects* / Q000378:metabolism; D012969:Sodium Fluoride / Q000494:pharmacology
D011943:Receptors, Adrenergic, beta; D005576:Colforsin; D000408:Alamethicin; D006165:Guanylyl Imidodiphosphate; D000255:Adenosine Triphosphate; D012969:Sodium Fluoride; D019204:GTP-Binding Proteins; D000262:Adenylyl Cyclases